Open Payments

Karmanos Cancer Hospital

Type
Teaching hospital
Where
Detroit, MI
Medicare CCN
230297
Received
$13,322,223 in 2,675 records, 2020 ($17,059 general, $13,305,163 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2020General payment5$17,059
2020Research payment2,670$13,305,163

By company

CompanyRecordsAmountYears
Alkermes, Inc.232$3,196,8652020
Merck Sharp & Dohme LLC754$2,247,9912020
Celgene Corporation12$1,074,8752020
E.R. Squibb & Sons, L.L.C.17$741,8452020
Genentech, Inc.155$634,4022020
PFIZER INC.109$539,5782020
Janssen Research & Development, LLC199$517,4902020
AstraZeneca Pharmaceuticals LP19$454,2822020
Regeneron Pharmaceuticals, Inc.61$400,3462020
Daiichi Sankyo Inc.235$399,9392020
Exelixis Inc.82$365,8192020
SEAGEN INC.94$334,2342020
Takeda Pharmaceuticals U.S.A., Inc.118$313,3512020
BIOVERATIV THERAPEUTICS INC.66$277,4042020
Boehringer Ingelheim Pharmaceuticals, Inc.3$181,9492020
Radius Health, Inc.35$180,4862020
Boehringer Ingelheim International GmbH48$160,1822020
Novartis Pharmaceuticals Corporation5$113,5862020
Clovis Oncology, Inc.15$97,5922020
Pharmacyclics LLC, an AbbVie Company61$90,4012020
Bayer Healthcare Pharmaceuticals Inc.29$85,2462020
AstraZeneca UK Limited8$73,6752020
EMD Serono, Inc.7$59,4842020
Corcept Therapeutics12$57,7162020
GlaxoSmithKline, LLC.8$55,8692020
Incyte Corporation62$54,8142020
Novocure Inc.37$51,9802020
Varian Medical Systems, Inc.2$49,8662020
CSL Behring8$48,7092020
Eli Lilly and Company8$46,0062020
Eisai Inc.31$43,3002020
Astellas Pharma Global Development10$40,2322020
Kite Pharma, Inc.16$34,9542020
Immunomedics, Inc.9$28,7862020
Ipsen Bioscience Inc.1$26,6602020
Acerta Pharma LLC1$25,9272020
ABBVIE INC.12$22,8442020
TAIHO ONCOLOGY, INC.16$21,2652020
Karyopharm Therapeutics Inc.3$20,7602020
F. Hoffmann-La Roche AG4$20,6692020
Geistlich Pharma, North America, Inc.9$19,8982020
BeiGene, Ltd.11$16,4632020
PUMA BIOTECHNOLOGY, INC.6$15,0912020
ARRAY BIOPHARMA INC5$14,8932020
Daiichi Sankyo Company LTD8$14,8302020
SANOFI US SERVICES INC.6$14,7982020
Dynavax Technologies Corporation5$9,6622020
Roche Products Limited1$8,2122020
Hoffmann-La Roche Limited5$6,7032020
Alnylam Pharmaceuticals Inc.8$4,3582020

By nature of payment

NatureRecordsAmount
Research payment2,670$13,305,163
Compensation for services other than consulting, including serving as faculty or as a speaker at a v5$17,059

Records

DateCompanyAmountNatureFormProductStudyYear
2020-12-31AstraZeneca Pharmaceuticals LP$14,927Research paymentIn-kind items and servicesIMFINZI Drug, OncologyA Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combinatio2020
2020-12-31CSL Behring$9,088Research paymentCash or cash equivalentZemaira Biological, Pulmonary/Respiratory DiseasesA Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined With 2020
2020-12-31AstraZeneca Pharmaceuticals LP$5,952Research paymentIn-kind items and servicesIMFINZI Drug, OncologyA Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Co2020
2020-12-31Alkermes, Inc.$4,410Research paymentIn-kind items and servicesA Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i2020
2020-12-31Janssen Research & Development, LLC$1,799Research paymentCash or cash equivalentA Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Rep2020
2020-12-31Genentech, Inc.$1,500Research paymentCash or cash equivalentRituxan Biological, BioOncology/ImmunologyPH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH22020
2020-12-31Genentech, Inc.$1,320Research paymentCash or cash equivalentRituxan Biological, BioOncology/ImmunologyPH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH22020
2020-12-31Genentech, Inc.$1,320Research paymentCash or cash equivalentRituxan Biological, BioOncology/ImmunologyPH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH22020
2020-12-31Genentech, Inc.$1,320Research paymentCash or cash equivalentRituxan Biological, BioOncology/ImmunologyPH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH22020
2020-12-31Janssen Research & Development, LLC$1,000Research paymentCash or cash equivalentA Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study2020
2020-12-31AstraZeneca Pharmaceuticals LP$779Research paymentIn-kind items and servicesPh2a Montherapy RCC study2020
2020-12-31Janssen Research & Development, LLC$650Research paymentCash or cash equivalentA Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study2020
2020-12-31AstraZeneca Pharmaceuticals LP$67Research paymentIn-kind items and servicesStudy of MEDI4736 Durvalumab With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer2020
2020-12-31AstraZeneca Pharmaceuticals LP$3Research paymentIn-kind items and servicesLYNPARZA Drug, OncologyThis is a non randomized open label study to assess olaparib tablets as a treatment for subjects with different homologo2020
2020-12-29Merck Sharp & Dohme LLC$19,541Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-r2020
2020-12-29Merck Sharp & Dohme LLC$10,539Research paymentCash or cash equivalentMK-7339 Drug, ONCOLOGYA Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizu2020
2020-12-29Merck Sharp & Dohme LLC$2,556Research paymentCash or cash equivalentMK-7339 Drug, ONCOLOGYA Phase 3 Study of Pembrolizumab in Combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel Followed by Pembrol2020
2020-12-29Amgen Inc.$1,490Research paymentCash or cash equivalentBlincyto Biological, OncologyAn OR study of patients with Relapsed/Refractory Acute Lymphoblastic Leukemia in the US - Serial CR2020
2020-12-24Alkermes, Inc.$15,787Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-12-24Alkermes, Inc.$15,787Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-12-24Alkermes, Inc.$15,787Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-12-24Alkermes, Inc.$15,710Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-12-24Alkermes, Inc.$3,100Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-12-24Alkermes, Inc.$3,100Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-12-24Alkermes, Inc.$3,100Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-12-24Alkermes, Inc.$322Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-12-24Daiichi Sankyo Inc.$69Research paymentCash or cash equivalentEnhertu Drug, Oncology2020
2020-12-23SEAGEN INC.$429Research paymentCash or cash equivalentADCETRIS Biological, OncologyA Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory H2020
2020-12-23SEAGEN INC.$231Research paymentCash or cash equivalentOpen Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in o2020
2020-12-22SEAGEN INC.$27,456Research paymentCash or cash equivalentTUKYSA Drug, Oncology2020
2020-12-22ABBVIE INC.$2,647Research paymentCash or cash equivalentM19-8942020
2020-12-22Merck Sharp & Dohme LLC$2,500Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Do2020
2020-12-22ABBVIE INC.$2,000Research paymentCash or cash equivalentM19-8942020
2020-12-22Incyte Corporation$1,599Research paymentCash or cash equivalentA Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin2020
2020-12-22Bayer Healthcare Pharmaceuticals Inc.$1,500Research paymentCash or cash equivalentNon-CoveredBAY94-9343 Solid Tumor Multi Cohort Trial2020
2020-12-22Bayer Healthcare Pharmaceuticals Inc.$1,320Research paymentCash or cash equivalentNon-CoveredBAY94-9343 Solid Tumor Multi Cohort Trial2020
2020-12-22Incyte Corporation$1,000Research paymentCash or cash equivalentA Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin2020
2020-12-22Bayer Healthcare Pharmaceuticals Inc.$1,000Research paymentCash or cash equivalentNon-CoveredBAY94-9343 Solid Tumor Multi Cohort Trial2020
2020-12-21Janssen Research & Development, LLC$6,102Research paymentCash or cash equivalentA Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody,2020
2020-12-21BIOVERATIV THERAPEUTICS INC.$4,559Research paymentCash or cash equivalentA Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for A2020
2020-12-21BIOVERATIV THERAPEUTICS INC.$1,320Research paymentCash or cash equivalentA Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for A2020
2020-12-21Genentech, Inc.$1,171Research paymentCash or cash equivalent DrugPHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE2020
2020-12-21Merck Sharp & Dohme LLC$579Research paymentIn-kind items and servicesMK-7339 Drug, ONCOLOGYA Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizu2020
2020-12-18Merck Sharp & Dohme LLC$32,569Research paymentIn-kind items and servicesMK-7339 Drug, ONCOLOGYA Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizu2020
2020-12-18Janssen Research & Development, LLC$1,500Research paymentCash or cash equivalentA Phase 1, First-in-Human, Dose Escalation Study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in Subject2020
2020-12-18Janssen Research & Development, LLC$1,320Research paymentCash or cash equivalentA Phase 1, First-in-Human, Dose Escalation Study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in Subject2020
2020-12-18Genentech, Inc.$894Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyNEOADJUVANT NSCLC2020
2020-12-18Janssen Research & Development, LLC$750Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez2020
2020-12-18Merck Sharp & Dohme LLC$426Research paymentIn-kind items and servicesMK-7339 Drug, ONCOLOGYA Phase 3 Study of Pembrolizumab in Combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel Followed by Pembrol2020
2020-12-18Janssen Research & Development, LLC$200Research paymentCash or cash equivalentA Phase 1, First-in-Human, Dose Escalation Study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in Subject2020
2020-12-18Merck Sharp & Dohme LLC$29Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatini2020
2020-12-17Alkermes, Inc.$319,398Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-12-17Alkermes, Inc.$16,120Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-12-17Alkermes, Inc.$15,787Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-12-17Alkermes, Inc.$15,787Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-12-17Alkermes, Inc.$15,710Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-12-17Alkermes, Inc.$15,710Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-12-17Alkermes, Inc.$15,710Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-12-17Alkermes, Inc.$15,710Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-12-17Pharmacyclics LLC, an AbbVie Company$8,600Research paymentCash or cash equivalentImbruvica Drug, OncologyPCYC-1143-CA2020
2020-12-17Janssen Research & Development, LLC$7,456Research paymentCash or cash equivalentA Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA2020
2020-12-17Exelixis Inc.$6,239Research paymentCash or cash equivalentCabozantinib Drug, OncologyStudy of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors2020
2020-12-17Takeda Pharmaceuticals U.S.A., Inc.$5,346Research paymentCash or cash equivalentA GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULT2020
2020-12-17Exelixis Inc.$3,800Research paymentCash or cash equivalentCabozantinib Drug, OncologyA Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus2020
2020-12-17Pharmacyclics LLC, an AbbVie Company$3,700Research paymentCash or cash equivalentImbruvica Drug, OncologyPCYC-1143-CA2020
2020-12-17Alkermes, Inc.$3,100Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-12-17Alkermes, Inc.$3,100Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-12-17Alkermes, Inc.$3,100Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-12-17ABBVIE INC.$2,953Research paymentCash or cash equivalentM19-8942020
2020-12-17Alkermes, Inc.$2,791Research paymentCash or cash equivalentA Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i2020
2020-12-17Alkermes, Inc.$2,522Research paymentIn-kind items and servicesA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-12-17PFIZER INC.$1,500Research paymentCash or cash equivalentBAVENCIO Drug, ONCOLOGYA RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS2020
2020-12-17Merck Sharp & Dohme LLC$1,126Research paymentIn-kind items and servicesMK-7339 Drug, ONCOLOGYA Phase 3 Study of Pembrolizumab in Combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel Followed by Pembrol2020
2020-12-17Alkermes, Inc.$1,000Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-12-17Regeneron Pharmaceuticals, Inc.$1,000Research paymentCash or cash equivalentPHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI2020
2020-12-17TAIHO ONCOLOGY, INC.$1,000Research paymentCash or cash equivalentTAS-1202020
2020-12-17Exelixis Inc.$858Research paymentCash or cash equivalentCabozantinib Drug, OncologyStudy of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors2020
2020-12-17Regeneron Pharmaceuticals, Inc.$755Research paymentCash or cash equivalentPHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI2020
2020-12-17Alkermes, Inc.$591Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-12-17Regeneron Pharmaceuticals, Inc.$400Research paymentCash or cash equivalentPHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI2020
2020-12-17TAIHO ONCOLOGY, INC.$224Research paymentCash or cash equivalentTAS-1202020
2020-12-17Alkermes, Inc.$83Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-12-16Merck Sharp & Dohme LLC$10,480Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase I,II Study of MK-3475 SCH900475 in Combination with Chemotherapy and,or Immunotherapy in Patients with Locally A2020
2020-12-16SEAGEN INC.$1,000Research paymentCash or cash equivalentOpen Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in o2020
2020-12-16Merck Sharp & Dohme LLC$237Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYAn Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly2020
2020-12-15Merck Sharp & Dohme LLC$27,650Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-r2020
2020-12-15GlaxoSmithKline, LLC.$11,768Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB2020
2020-12-15Takeda Pharmaceuticals U.S.A., Inc.$8,307Research paymentCash or cash equivalentA STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF TAK-981 IN ADULT PARTICIPANTS WITH ADVANCED OR2020
2020-12-15Merck Sharp & Dohme LLC$2,200Research paymentCash or cash equivalentMK-7339 Drug, ONCOLOGYA Phase 3, Randomized, Open-label Study of Pembrolizumab MK-3475 Plus Olaparib Versus Abiraterone Acetate or Enzalutamid2020
2020-12-15Takeda Pharmaceuticals U.S.A., Inc.$1,568Research paymentCash or cash equivalentICLUSIG Drug, ONCOLOGYA RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA T2020
2020-12-15Regeneron Pharmaceuticals, Inc.$1,500Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2020
2020-12-15Regeneron Pharmaceuticals, Inc.$990Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2020
2020-12-15Regeneron Pharmaceuticals, Inc.$660Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2020
2020-12-15Regeneron Pharmaceuticals, Inc.$660Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2020
2020-12-15Clovis Oncology, Inc.$429Research paymentCash or cash equivalentRubraca Drug, ONCOLOGYA Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, Hi2020
2020-12-15Exelixis Inc.$400Research paymentCash or cash equivalentCabozantinib Drug, OncologyA Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus2020
2020-12-15Regeneron Pharmaceuticals, Inc.$300Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2020
2020-12-15Immunomedics, Inc.$55Research paymentCash or cash equivalentTrodelvy Drug, OncologyIMMU-132-112020
2020-12-14Genentech, Inc.$5,265Research paymentCash or cash equivalent DrugPHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE2020
2020-12-14Janssen Research & Development, LLC$2,500Research paymentCash or cash equivalentA Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody,2020
2020-12-14Janssen Research & Development, LLC$2,181Research paymentCash or cash equivalentA Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody,2020
2020-12-14Janssen Research & Development, LLC$1,500Research paymentCash or cash equivalentA Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody,2020
2020-12-14Janssen Research & Development, LLC$1,320Research paymentCash or cash equivalentA Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody,2020
2020-12-14Janssen Research & Development, LLC$1,000Research paymentCash or cash equivalentA Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody,2020
2020-12-14Janssen Research & Development, LLC$677Research paymentCash or cash equivalentA Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody,2020
2020-12-14Janssen Research & Development, LLC$400Research paymentCash or cash equivalentA Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody,2020
2020-12-14Janssen Research & Development, LLC$130Research paymentCash or cash equivalentA Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody,2020
2020-12-14Janssen Research & Development, LLC$56Research paymentCash or cash equivalentA Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody,2020
2020-12-10Daiichi Sankyo Inc.$5,765Research paymentCash or cash equivalentEnhertu Drug, Oncology2020
2020-12-10Janssen Research & Development, LLC$4,334Research paymentCash or cash equivalentA Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA2020
2020-12-10Janssen Research & Development, LLC$3,681Research paymentCash or cash equivalentA Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA2020
2020-12-10Janssen Research & Development, LLC$1,500Research paymentCash or cash equivalentA Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study2020
2020-12-10Pharmacyclics LLC, an AbbVie Company$1,215Research paymentCash or cash equivalentImbruvica Drug, OncologyPCYC-1123-CA2020
2020-12-10Merck Sharp & Dohme LLC$1,000Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refracto2020
2020-12-10Janssen Research & Development, LLC$650Research paymentCash or cash equivalentA Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study2020
2020-12-09Radius Health, Inc.$13,040Research paymentCash or cash equivalentA Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Canc2020
2020-12-09Genentech, Inc.$3,150Research paymentCash or cash equivalentHerceptin Biological, BioOncologyA PHASE III TRIAL IN ADJUVANT HER2 BC PTS2020
2020-12-09SEAGEN INC.$1,000Research paymentCash or cash equivalentA Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies2020
2020-12-09SEAGEN INC.$1,000Research paymentCash or cash equivalentOpen Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in o2020
2020-12-09Genentech, Inc.$1,000Research paymentCash or cash equivalentAvastin Biological, BioOncologyTECENTRIQ ONCOLOGY EXTENSION STUDY2020
2020-12-09SEAGEN INC.$1,000Research paymentCash or cash equivalentA Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies2020
2020-12-09Alkermes, Inc.$757Research paymentIn-kind items and servicesA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-12-09Alkermes, Inc.$518Research paymentIn-kind items and servicesA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-12-09Merck Sharp & Dohme LLC$381Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase II,III Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with 2020
2020-12-08Genentech, Inc.$29,362Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyNEOADJUVANT NSCLC2020
2020-12-08Merck Sharp & Dohme LLC$27,650Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-r2020
2020-12-08Regeneron Pharmaceuticals, Inc.$2,649Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2020
2020-12-08Regeneron Pharmaceuticals, Inc.$1,000Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2020
2020-12-07Merck Sharp & Dohme LLC$305Research paymentIn-kind items and servicesMK-7684 Drug, ONCOLOGYPhase I Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumor2020
2020-12-04Merck Sharp & Dohme LLC$19,541Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-r2020
2020-12-04Janssen Research & Development, LLC$9,851Research paymentCash or cash equivalentA Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody,2020
2020-12-04Merck Sharp & Dohme LLC$1,500Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemother2020
2020-12-04Geistlich Pharma, North America, Inc.$755Research paymentCash or cash equivalentPhase 1/2 Trial to Evaluate the safety, tolerability, Pharmacokinetics and preliminary efficacy of GP-2250 in combinatio2020
2020-12-03Daiichi Sankyo Inc.$60,027Research paymentCash or cash equivalentEnhertu Drug, Oncology2020
2020-12-03Daiichi Sankyo Inc.$3,301Research paymentCash or cash equivalentEnhertu Drug, Oncology2020
2020-12-03BIOVERATIV THERAPEUTICS INC.$2,640Research paymentCash or cash equivalentA Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for A2020
2020-12-03Daiichi Sankyo Inc.$2,232Research paymentCash or cash equivalentEnhertu Drug, Oncology2020
2020-12-03Pharmacyclics LLC, an AbbVie Company$1,569Research paymentCash or cash equivalentImbruvica Drug, OncologyPCYC-1143-CA2020
2020-12-03Pharmacyclics LLC, an AbbVie Company$1,500Research paymentCash or cash equivalentImbruvica Drug, OncologyPCYC-1140-IM2020
2020-12-03Pharmacyclics LLC, an AbbVie Company$1,320Research paymentCash or cash equivalentImbruvica Drug, OncologyPCYC-1140-IM2020
2020-12-03Daiichi Sankyo Inc.$1,000Research paymentCash or cash equivalentEnhertu Drug, Oncology2020
2020-12-03BeiGene, Ltd.$1,000Research paymentCash or cash equivalentBRUKINSA Drug, ONCOLOGYA Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine2020
2020-12-03Merck Sharp & Dohme LLC$1,000Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for 2020
2020-12-03Pharmacyclics LLC, an AbbVie Company$990Research paymentCash or cash equivalentImbruvica Drug, OncologyPCYC-1140-IM2020
2020-12-03Daiichi Sankyo Inc.$942Research paymentCash or cash equivalentEnhertu Drug, Oncology2020
2020-12-03Daiichi Sankyo Inc.$755Research paymentCash or cash equivalentEnhertu Drug, Oncology2020
2020-12-03Janssen Research & Development, LLC$750Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez2020
2020-12-03Daiichi Sankyo Inc.$678Research paymentCash or cash equivalentEnhertu Drug, Oncology2020
2020-12-03Daiichi Sankyo Inc.$524Research paymentCash or cash equivalentEnhertu Drug, Oncology2020
2020-12-03Daiichi Sankyo Inc.$400Research paymentCash or cash equivalentEnhertu Drug, Oncology2020
2020-12-03Daiichi Sankyo Inc.$400Research paymentCash or cash equivalentEnhertu Drug, Oncology2020
2020-12-03Daiichi Sankyo Inc.$230Research paymentCash or cash equivalentEnhertu Drug, Oncology2020
2020-12-03Daiichi Sankyo Inc.$186Research paymentCash or cash equivalentEnhertu Drug, Oncology2020
2020-12-03Daiichi Sankyo Inc.$91Research paymentCash or cash equivalentEnhertu Drug, Oncology2020
2020-12-03Daiichi Sankyo Inc.$41Research paymentCash or cash equivalentEnhertu Drug, Oncology2020
2020-12-02Merck Sharp & Dohme LLC$1,000Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemother2020
2020-12-02Merck Sharp & Dohme LLC$1,000Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemother2020
2020-12-01Merck Sharp & Dohme LLC$21,600Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb 22841 Monotherapy and in Combination with 2020
2020-12-01Merck Sharp & Dohme LLC$6,950Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with2020
2020-12-01Immunomedics, Inc.$2,999Research paymentCash or cash equivalentTrodelvy Drug, OncologyIMMU-132-112020
2020-12-01AstraZeneca UK Limited$2,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentLYNPARZA Drug, Oncology2020
2020-12-01Takeda Pharmaceuticals U.S.A., Inc.$1,500Research paymentCash or cash equivalentALUNBRIG Drug, ONCOLOGYBRIGATINIB IN PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK+), ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PROG2020
2020-12-01Takeda Pharmaceuticals U.S.A., Inc.$1,320Research paymentCash or cash equivalentALUNBRIG Drug, ONCOLOGYBRIGATINIB IN PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK+), ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PROG2020
2020-12-01Merck Sharp & Dohme LLC$1,000Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-792020
2020-12-01Merck Sharp & Dohme LLC$1,000Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-792020
2020-12-01AstraZeneca UK Limited$618Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentLYNPARZA Drug, Oncology2020
2020-12-01Immunomedics, Inc.$154Research paymentCash or cash equivalentTrodelvy Drug, OncologyIMMU-132-112020
2020-11-30Merck Sharp & Dohme LLC$5,656Research paymentCash or cash equivalentMK-7339 Drug, ONCOLOGYA Phase 3 Study of Pembrolizumab in Combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel Followed by Pembrol2020
2020-11-30Merck Sharp & Dohme LLC$1,000Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand2020
2020-11-30Merck Sharp & Dohme LLC$1,000Research paymentCash or cash equivalentMK-7339 Drug, ONCOLOGYA Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizu2020
2020-11-30Janssen Research & Development, LLC$975Research paymentCash or cash equivalentA Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study2020
2020-11-27Merck Sharp & Dohme LLC$1,000Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus 2020
2020-11-27Merck Sharp & Dohme LLC$1,000Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus 2020
2020-11-27Merck Sharp & Dohme LLC$1,000Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus 2020
2020-11-26Alkermes, Inc.$25,710Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-11-26Alkermes, Inc.$23,710Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-11-26Alkermes, Inc.$15,710Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-11-26Alkermes, Inc.$15,710Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-11-26Alkermes, Inc.$15,710Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-11-26Alkermes, Inc.$15,710Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-11-26Alkermes, Inc.$15,710Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-11-26Alkermes, Inc.$3,100Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-11-26Alkermes, Inc.$3,100Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-11-26Alkermes, Inc.$3,100Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-11-26Alkermes, Inc.$3,100Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-11-26Alkermes, Inc.$2,800Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-11-26Alkermes, Inc.$2,399Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-11-26Regeneron Pharmaceuticals, Inc.$2,181Research paymentCash or cash equivalentPHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI2020
2020-11-26Regeneron Pharmaceuticals, Inc.$1,500Research paymentCash or cash equivalentPHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI2020
2020-11-26Daiichi Sankyo Inc.$1,500Research paymentCash or cash equivalentEnhertu Drug, Oncology2020
2020-11-26Regeneron Pharmaceuticals, Inc.$1,320Research paymentCash or cash equivalentPHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI2020
2020-11-26Alkermes, Inc.$1,000Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-11-26Regeneron Pharmaceuticals, Inc.$400Research paymentCash or cash equivalentPHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI2020
2020-11-26Alkermes, Inc.$243Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-11-26Alkermes, Inc.$142Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-11-26Alkermes, Inc.$142Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-11-26Alkermes, Inc.$23Research paymentCash or cash equivalentA Study of the Effects of ALKS 4230 on Subjects With Solid Tumors2020
2020-11-25AstraZeneca UK Limited$2,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentLYNPARZA Drug, Oncology2020
2020-11-25Novocure Inc.$1,730Research paymentCash or cash equivalentOptune Device, OncologyEF-25 Pivotal, oopen-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 2020
2020-11-25Novocure Inc.$1,080Research paymentCash or cash equivalentOptune Device, OncologyEF-25 Pivotal, oopen-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 2020

The latest 200 records of 2,675.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Wayne CountyDetroit city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Detroit, MI, county Wayne County, MI, state Michigan; placed by its city name.

MeasurePlace (city or town)
Detroit, MI
County
Wayne County, MI
State
Michigan
Population B01003638,5301,772,25910,077,761
Population, 2020 census P1639,1111,793,56110,077,331
Median age B0100235.237.940.2
Under 18 B0100124.8%23.6%21.2%
65 and over B0100115.1%16.6%18.6%
Households B11001257,998700,5914,076,369
Foreign born B050026.6%10.3%7.2%
Median household income B19013$39,938$60,539$72,875
Median family income B19113$49,398$79,522$93,357
Per capita income B19301$24,594$34,906$40,735
Poverty rate B1700132.7%20.8%13.2%
Unemployment rate B2302514.0%8.7%5.7%
Civilian labor force B23025268,955828,8385,018,449
Mean commute (minutes) B0801324.824.724.2
Bachelor's degree or higher B1500318.1%27.6%32.4%
Housing units B25001329,393801,0834,622,236
Owner-occupied B2500350.3%64.8%73.2%
Renters B2500349.7%35.2%26.8%
Median home value B25077$83,900$178,500$231,600
Median gross rent B25064$1,074$1,132$1,129
White, not Hispanic B0300210.8%47.9%72.4%
Black B0300275.0%36.6%13.1%
Hispanic or Latino B030028.3%6.9%5.9%
Asian B030021.7%3.7%3.4%
American Indian and Alaska Native B030020.2%0.2%0.3%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Detroit, MI.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.